{"title":"Dopamine D2 receptor antagonists alter autophosphorylation of focal adhesion kinases in the mouse forebrain in vivo","authors":"Li-Min Mao , Tayyibah Mahmood , John Q. Wang","doi":"10.1016/j.neulet.2025.138145","DOIUrl":null,"url":null,"abstract":"<div><div>Focal adhesion kinase (FAK) is a non-receptor tyrosine kinase expressed in neurons of the developing and adult brain in addition to non-neuronal cells. Activation of FAK is initiated by autophosphorylation of the kinase at tyrosine 397 (Y397). Active FAK transmits extracellular signals inside neurons to integrate cytoskeletal rearrangements and modulate synaptic transmission and plasticity. Here we investigated roles of dopamine receptors, i.e., G<sub>αs/olf</sub>-coupled D<sub>1</sub> and G<sub>αi/o</sub>-coupled D<sub>2</sub> subtypes, in regulation of FAK autophosphorylation in two major dopamine-innervated areas of the mouse brain <em>in vivo</em>. We found that acute systemic administration of a dopamine D<sub>1</sub> or D<sub>2</sub> receptor agonist had no effect on basal FAK autophosphorylation at Y397 in the striatum and medial prefrontal cortex (mPFC). Similarly, a D<sub>1</sub> receptor antagonist did not alter striatal and cortical Y397 phosphorylation. However, acute injection of a D<sub>2</sub> receptor antagonist (eticlopride or haloperidol) induced a marked increase in Y397 phosphorylation in the striatum and mPFC. The eticlopride-induced Y397 phosphorylation can be seen in the two striatal subdivisions, the caudate putamen and nucleus accumbens, and was induced at two effective doses (0.1 and 0.5 mg/kg). All drug treatments caused insignificant changes in cellular FAK protein expression. These results reveal an existence of a tonic inhibitory tone of dopamine D<sub>2</sub> receptors over basal FAK autophosphorylation in the mouse striatum and mPFC.</div></div>","PeriodicalId":19290,"journal":{"name":"Neuroscience Letters","volume":"850 ","pages":"Article 138145"},"PeriodicalIF":2.5000,"publicationDate":"2025-01-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neuroscience Letters","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0304394025000333","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"NEUROSCIENCES","Score":null,"Total":0}
引用次数: 0
Abstract
Focal adhesion kinase (FAK) is a non-receptor tyrosine kinase expressed in neurons of the developing and adult brain in addition to non-neuronal cells. Activation of FAK is initiated by autophosphorylation of the kinase at tyrosine 397 (Y397). Active FAK transmits extracellular signals inside neurons to integrate cytoskeletal rearrangements and modulate synaptic transmission and plasticity. Here we investigated roles of dopamine receptors, i.e., Gαs/olf-coupled D1 and Gαi/o-coupled D2 subtypes, in regulation of FAK autophosphorylation in two major dopamine-innervated areas of the mouse brain in vivo. We found that acute systemic administration of a dopamine D1 or D2 receptor agonist had no effect on basal FAK autophosphorylation at Y397 in the striatum and medial prefrontal cortex (mPFC). Similarly, a D1 receptor antagonist did not alter striatal and cortical Y397 phosphorylation. However, acute injection of a D2 receptor antagonist (eticlopride or haloperidol) induced a marked increase in Y397 phosphorylation in the striatum and mPFC. The eticlopride-induced Y397 phosphorylation can be seen in the two striatal subdivisions, the caudate putamen and nucleus accumbens, and was induced at two effective doses (0.1 and 0.5 mg/kg). All drug treatments caused insignificant changes in cellular FAK protein expression. These results reveal an existence of a tonic inhibitory tone of dopamine D2 receptors over basal FAK autophosphorylation in the mouse striatum and mPFC.
期刊介绍:
Neuroscience Letters is devoted to the rapid publication of short, high-quality papers of interest to the broad community of neuroscientists. Only papers which will make a significant addition to the literature in the field will be published. Papers in all areas of neuroscience - molecular, cellular, developmental, systems, behavioral and cognitive, as well as computational - will be considered for publication. Submission of laboratory investigations that shed light on disease mechanisms is encouraged. Special Issues, edited by Guest Editors to cover new and rapidly-moving areas, will include invited mini-reviews. Occasional mini-reviews in especially timely areas will be considered for publication, without invitation, outside of Special Issues; these un-solicited mini-reviews can be submitted without invitation but must be of very high quality. Clinical studies will also be published if they provide new information about organization or actions of the nervous system, or provide new insights into the neurobiology of disease. NSL does not publish case reports.